Endotronix

Endotronix is a cardiovascular medical device company specializing in remote hemodynamic monitoring systems for heart failure management. The company manufactures the Cordella PA Sensor and HF System, an FDA-approved implantable pulmonary artery pressure sensor designed for patients with NYHA class III heart failure. The Cordella system enables proactive, remote monitoring by collecting daily pulmonary artery pressure data alongside vital signs including blood pressure, weight, heart rate, and blood oxygen saturation. The integrated HF management platform provides clinicians with comprehensive, trended health data to guide medication optimization and reduce hospitalizations. Clinical evidence demonstrates the system achieved a 73% reduction in heart failure hospitalization rates at 12 months and a low 12-month hospitalization/all-cause mortality rate (0.36) in the PROACTIVE-HF trial. The platform combines patient-facing monitoring tools with clinician-directed workflows that align with care delivery models and support reimbursement. The company holds FDA approval for the Cordella system and focuses on advancing guideline-directed medical therapy adoption. Endotronix was acquired by Edwards Lifesciences in 2024 for $1.2 billion, integrating its hemodynamic monitoring technology into a major cardiovascular device portfolio.